Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will report Q3 financial results on November 10, 2021, before the market opens. Management will host a webcast at 8:30 a.m. ET to discuss results, business advancements, and future outlook. The SOPHiA DDM™ Platform, their cloud-based SaaS solution, is utilized by over 780 institutions globally, aiming to set data-driven medicine as a standard. The live audio will be available on the company’s Investors section of the website, with an archived replay afterwards.
SOPHiA GENETICS (Nasdaq: SOPH) has launched the SOPHiA Clinical Exome Solution v3, which enhances probe design and detection capabilities for investigating Mendelian diseases. This application combines a capture-based target enrichment kit with the SOPHiA DDM™ platform, achieving over 90% analytical sensitivity for CNV detection. Enhanced probe design allows for improved detection of rare disorders across the mitochondrial genome and 280 known disorder-causing genomic locations. This innovation aims to streamline data analysis and improve institutional resource efficiency.
SOPHiA GENETICS (NASDAQ: SOPH) reported Q2 2021 revenue of $10.2 million, a 72% increase Year-over-Year (YoY). The customer base grew to 780. The company raised approximately $217 million from its IPO and $20 million from a private placement. Q2 gross profit was $6.2 million, with a margin of 61%, down from 67% in Q2 2020. Operating expenses rose to $22.2 million, leading to a net loss of $18.4 million. For 2021, revenue guidance exceeds $39 million, projecting over 37% growth.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. The presentation is scheduled for 9:30 a.m. Eastern Time/3:30 p.m. Central European Time and will be accessible via a live and archived webcast on the company’s website.
The company is a leader in data-driven medicine and offers the SOPHiA DDM™ Platform, which supports over 780 institutions globally in analyzing complex data sets for healthcare and life sciences.
SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2021 financial results on September 9, 2021, before market open. The management will host a conference call at 8:30 a.m. ET to discuss these results, alongside business developments and future outlook. The company focuses on data-driven medicine and operates the SOPHiA DDM™ Platform, utilized by over 780 institutions globally. A live webcast of the call will be accessible in the 'Investors' section of their website, with an archived replay available post-event.
SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q2 2021 on September 9, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss these results, business developments, and future outlook. The company emphasizes its commitment to data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 780 healthcare institutions globally, reinforcing its strategic position in the healthcare technology landscape.
Dasa, Brazil's largest healthcare network, is expanding its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to launch the first decentralized HRD analytics solution in Latin America. This solution focuses on identifying cancer patients who may benefit from PARP inhibitors, promoting personalized therapies. With over 20 million patient interactions yearly, Dasa enhances its genomic capabilities using SOPHiA's platform, built on a collaboration that started in 2016. This innovation aims to improve patient outcomes through efficient data management and tailored treatment strategies.
SOPHiA GENETICS (Nasdaq: SOPH) has successfully closed its initial public offering, selling 13,000,000 ordinary shares at $18 each, generating gross proceeds of $234 million. Following this, the company also completed a private placement, issuing 1,111,111 ordinary shares to GE Healthcare for $20 million. The new shares began trading on the Nasdaq on July 23, 2021. J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse were joint book-running managers for the IPO.
SOPHiA GENETICS has announced the pricing of its initial public offering (IPO) of 13,000,000 ordinary shares at $18 each, aiming to raise around $234 million in gross proceeds. The IPO is set to trade on the Nasdaq under the symbol 'SOPH' starting July 23, 2021, with the closing expected on July 27, 2021. Additionally, underwriters have a 30-day option to purchase up to 1,950,000 more shares. The company specializes in data-driven medicine through its SOPHiA DDM™ Platform, which serves over 780 institutions worldwide.